Yongpeng Shi, Zeran Chen, Tingyu Fang, Xingyao Chen, Youpeng Deng, Hao Qin, Min Lian, Juntao Shen, Yuru Zong, Huikuan Chu, Constanze Hoebinger, Hao Guo, Zhongshang Yuan, Jie Zheng, Yongjian Zhou, Yue Pan, Beatriz G. Mendes, Sonja Lang, Tim Hendrikx, Suling Zeng, Hailong Cao, Ling Yang, Lianmin Chen, Peng Chen, Lei Dai, Hua Wang, Shi Yin, Shu Zhu, Xiong Ma, Bernd Schnabl, Hanqing Chen, Yi Duan
{"title":"Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities","authors":"Yongpeng Shi, Zeran Chen, Tingyu Fang, Xingyao Chen, Youpeng Deng, Hao Qin, Min Lian, Juntao Shen, Yuru Zong, Huikuan Chu, Constanze Hoebinger, Hao Guo, Zhongshang Yuan, Jie Zheng, Yongjian Zhou, Yue Pan, Beatriz G. Mendes, Sonja Lang, Tim Hendrikx, Suling Zeng, Hailong Cao, Ling Yang, Lianmin Chen, Peng Chen, Lei Dai, Hua Wang, Shi Yin, Shu Zhu, Xiong Ma, Bernd Schnabl, Hanqing Chen, Yi Duan","doi":"10.1002/imt2.265","DOIUrl":null,"url":null,"abstract":"<p>Accumulating evidence indicates that the gut microbiota is intricately involved in the initiation and progression of human diseases, forming a multidirectional regulatory axis centered on intestinal microbiota. This article illustrates the challenges in exploring the role of the gut microbiota in inflammatory digestive diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and inflammatory bowel disease (IBD), and summarizes the existing microbiome-focused treatment strategies (probiotics, prebiotics, symbiotics, fecal microbiota transplantation, and bacteriophages therapy), emerging technologies (gut microbiome-on-a-chip and artificial intelligence), as well as possible future research directions. Taken together, these therapeutic strategies and technologies present both opportunities and challenges, which require researchers and clinicians to test the rationality and feasibility of various therapeutic modalities in continuous practice.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":"4 1","pages":""},"PeriodicalIF":23.7000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.265","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Accumulating evidence indicates that the gut microbiota is intricately involved in the initiation and progression of human diseases, forming a multidirectional regulatory axis centered on intestinal microbiota. This article illustrates the challenges in exploring the role of the gut microbiota in inflammatory digestive diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and inflammatory bowel disease (IBD), and summarizes the existing microbiome-focused treatment strategies (probiotics, prebiotics, symbiotics, fecal microbiota transplantation, and bacteriophages therapy), emerging technologies (gut microbiome-on-a-chip and artificial intelligence), as well as possible future research directions. Taken together, these therapeutic strategies and technologies present both opportunities and challenges, which require researchers and clinicians to test the rationality and feasibility of various therapeutic modalities in continuous practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
